FDA Guidance On Post-Approval Changes for Drug Substances Closes Regulatory Gap
Executive Summary
FDA’s guidance on post-approval changes for drug substances fills in some of the missing pieces of the regulatory puzzle on how these changes are to be reported and documented. And it arrives just as FDA and other regulatory authorities are talking with industry about major upgrades to post-approval changes processes proposed in the International Council on Harmonization’s draft Q12 guideline.
You may also be interested in...
Pharmaceutical Industry Slams FDA’s Guidance On Drug Substance Post- Approval Changes; Say More Alignment With ICH Needed
Like the fabled Rip Van Winkle, FDA guidance on post-approval changes for drug substances has awakened after a long nap to a changed world. Industry is urging FDA to revise its draft in a way that’s less prescriptive and more in line with the science- and risk-based approaches, outlined in ICH Q8, Q9 and Q12 guidelines, that have emerged in the years after the agency withdrew its BACPAC guidance.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.